Caring Brands, Inc.

Caring Brands, Inc. is a wellness consumer products company offering a diverse range of over-the-counter (OTC) and cosmetic products, including hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, a jellyfish sting protective suncare line, and women's sexual wellness products. The company's operational methodology emphasizes establishing the mechanism of action for all products, determining efficacy through controlled clinical trials, protecting products with issued and filed patents, and ensuring acceptable commercial stability. The company operates in the global phototherapy treatment market, which is projected to grow from approximately $1.9 billion ¹ in 2023 to approximately $3.23 billion ² by 2033, at a CAGR of around 5.2% ³. The global psoriasis treatment market was valued at approximately $34 billion ⁴ in the 12 months ending June 2023, with the US market accounting for approximately 78% ⁵ of total sales and growing at an 18% ⁶ CAGR. The global vitiligo treatment market was valued at approximately $538.90 million ⁷ in 2024 and is projected to grow at a CAGR of 4.60% ⁸ to approximately $807.70 million ⁹ by 2034. The minoxidil market was valued at $1.5 billion ¹⁰ in 2022 and is expected to grow to $2.5 billion ¹¹ by 2032. The global eczema treatment market was valued at $14 billion ¹² in 2022.

The company's core business model revolves around developing and commercializing wellness consumer products, primarily OTC and cosmetic. Revenue generation is currently minimal as the company is in the early stages of commercialization. The company aims to sell products online directly through its own website and third-party marketplaces. Its primary customer segments are individuals seeking solutions for hair loss, eczema, psoriasis, vitiligo, and sun protection. The company's strategy includes leveraging unique mechanisms of action and clinical benefits to differentiate its products.

Caring Brands' product portfolio includes Photocil, a narrow-band UV filter for vitiligo and psoriasis, which was commercially launched in India in Q3 2022 and briefly in the US from December 2022 to February 2023. It is categorized as an OTC product in the US, using a USP monographed ingredient as a skin protectant with FDA-registered labeling. In India, it is marketed under local cosmetic regulations. The Hair Enzyme Booster (JW-700), previously Minoxidil Booster, was launched on Amazon on October 28, 2024, and on NOVODX's e-commerce platform on December 11, 2024. It is marketed as a cosmetic product in the U.S. and under local cosmetic regulations in India, designed to enhance minoxidil efficacy by increasing sulfotransferase enzymes. CB-101, a topical OTC treatment for atopic dermatitis (eczema) with aspartame and colloidal oatmeal, is planned for reformulation and anticipated to be available online in the US in Q2 2026. NoStingz, a sunscreen product providing protection against UV rays and jellyfish stings, is also planned for reformulation.

For the year ended December 31, 2025, the company generated revenue of $4,215 ¹³ with a cost of revenue of $1,873 ¹⁴, resulting in a gross profit of $2,342 ¹⁵. This compares to revenue of $465 ¹⁶ and cost of revenue of $2,072 ¹⁷ for the year ended December 31, 2024, which resulted in a gross loss of $(1,607) ¹⁸. The operating loss for 2025 was $(5,935,025) ¹⁹, compared to a total operating loss of $1,525,787 ²⁰ for 2024. The net loss for 2025 was $(6,278,191) ²¹, compared to a net loss of $1,517,431 ²² for 2024. Basic and diluted EPS for 2025 were both $(0.46) ²³. As of December 31, 2025, cash and cash equivalents totaled $2,189,232 ²⁴, up from $468,998 ²⁵ at December 31, 2024. Total assets decreased to $2,326,818 ²⁶ from $3,877,481 ²⁷ year-over-year, primarily due to a full impairment of intellectual property and investment balances. Total liabilities were $235,494 ²⁸ at December 31, 2025, compared to $186,105 ²⁹ at December 31, 2024. Net cash used in operating activities for 2025 was $1,692,258 ³⁰.

The company experienced a significant increase in operating expenses in 2025, totaling $5,937,367 ³¹, up from $1,525,787 ³² in 2024. This increase was driven by higher payroll expenses of $2,008,394 ³³ in 2025 compared to $912,744 ³⁴ in 2024, increased professional service fees of $931,279 ³⁵ in 2025 versus $359,709 ³⁶ in 2024, and a full year of amortization of the intellectual property license, which amounted to $300,000 ³⁷ in 2025 compared to $150,000 ³⁸ in 2024. A notable operational development was the recognition of an impairment loss on intellectual property of $2,550,000 ³⁹ in 2025, with no comparable impairment in prior periods. The company also recorded an impairment loss on its investment of $500,000 ⁴⁰ in 2025. In financing activities, the company completed an initial public offering in November 2025, generating net proceeds of $3,235,692 ⁴¹.

Management believes that existing cash resources of $2,189,232 ⁴² are sufficient to fund operations for at least the next twelve months. However, there is no assurance that additional capital will not be required for long-term growth initiatives, strategic investments, or acquisitions. The company may seek additional capital through equity offerings, debt financing, or other strategic transactions, but availability on acceptable terms is not guaranteed.

A major growth area for Caring Brands is the relaunch of Photocil in the United States, targeted for 2026. This product, a narrow band UV filter for vitiligo and psoriasis, was previously removed from the US market due to insufficient sales from a lack of a dedicated sales and marketing team. The product formulation has not changed, and the company plans to apply for a National Drug Code (NDC) number for FDA registration prior to relaunch. Management believes phototherapy treatments, used for conditions like psoriasis and vitiligo, are set for substantial global growth, with the Indian market expected to expand at an estimated CAGR of approximately 7.8% ⁴³. The global vitiligo treatment market is projected to grow at a CAGR of 4.60% ⁴⁴ from 2025 to 2034, reaching approximately $807.70 million ⁴⁵ by 2034.

Another growth vector is the Hair Enzyme Booster (JW-700), which was launched on Amazon on October 28, 2024, and NOVODX's e-commerce platform on December 11, 2024. The company is in the early stages of commercialization and is refining its marketing strategies for these platforms. Sales have been minimal during this initial soft launch period. The minoxidil market, which JW-700 is designed to enhance, was valued at $1.5 billion ⁴⁶ in 2022 and is expected to grow to $2.5 billion ⁴⁷ by 2032. The company has a license agreement with Taisho Pharmaceutical Co., Ltd., Japan's leading seller of minoxidil products, for exclusive rights in Japan, with an expected commercial launch in 2025. This agreement includes up to $200,000 ⁴⁸ in milestone payments and a 3% ⁴⁹ royalty on net sales.

The company plans to complete the reformulation of CB-101, an eczema treatment, in Q4 2025/Q1 2026, with an anticipated online availability in the US in Q2 2026 as an over-the-counter product under a USP monograph. Reformulation activities are currently in the exploratory phase, with $150,000 ⁵⁰ anticipated for formulation development, $200,000 ⁵¹ for the initial production run, and $50,000 ⁵² for clinical testing. The global eczema treatment market was valued at $14 billion ⁵³ in 2022.

Operationally, the company expects to continually update and expand its corporate website, CaringBrands.com, and further refine its online retail strategies. Each brand is anticipated to have its own front-facing website dedicated to retail sales and brand-specific information. A website dedicated to servicing wholesale and larger distributor clients is also being built. The company plans to seek acquisition opportunities in the branded consumer products space, including additional OTC/cosmetic therapeutic brands and skin care brands that can be manufactured, marketed, and distributed without additional FDA approval.

Planned capital allocation includes supporting ongoing operations, product development, and potential strategic initiatives using the remaining proceeds from the IPO. The company's R&D costs were $0 ⁵⁴ for the year ended December 31, 2025, compared to $39,558 ⁵⁵ for the year ended December 31, 2024. The company does not intend to declare or pay any dividends in the foreseeable future, as it plans to employ all available funds for the growth and development of its business.

The company faces structural headwinds and execution risks, including the highly fragmented and competitive consumer product industry, with larger, well-funded companies as competitors. The success of new product introductions depends on factors such as successful sales and marketing efforts, timely delivery, raw material availability and pricing, regulatory allowance, and customer acceptance. The company's ability to compete effectively and generate revenue will be based on its ability to create and expand brand awareness, which is limited by various advertising and labeling regulations. The company also faces risks related to its limited operating history, potential inability to keep up with rapid technological changes, and the need for adequate capital to fund its business.

Geographic, regulatory, and macro factors identified as constraints include varying international regulatory frameworks, such as the need for Central Drugs Standard Control Organization (CDSCO) approval in India. Failure to comply with regulatory requirements could result in product recalls, enforcement actions, manufacturing disruptions, reputational damage, and loss of market access. Changes in regulations or their interpretation may require significant resources and could delay product launches. The company's operations in international markets are subject to uncontrollable factors such as macroeconomic conditions, foreign currency exchange rates, political or social unrest, and trade protection measures.

Caring Brands faces significant risks, including a limited operating history and a going concern doubt due to recurring losses of $6,278,191 ⁵⁶ in 2025 and negative cash flows from operating activities of $1,692,258 ⁵⁷. The company may not have adequate capital to fund its business, and competition in the skin care and hair growth markets from larger, better-resourced companies could adversely affect market share and revenues. Regulatory risks are substantial, as the company's products are subject to FDA regulations for OTC and cosmetic products in the U.S. and international regulations, such as CDSCO approval in India. Disagreements with the FDA on product classification or failure to comply with regulations could lead to reformulation requirements, delays in the approval process, marketing cessation, or enforcement actions. Product liability claims, arising from potential illness or injury due to product use or interactions with other treatments, pose an inherent risk, potentially increasing costs through higher insurance premiums and deductibles. The company has identified material weaknesses in its internal controls over financial reporting, specifically ineffective controls over period-end financial disclosure and reporting processes, including reconciliations and the completeness and accuracy of those reconciliations, and a lack of effectiveness of controls over accurate accounting and financial reporting and reviewing underlying financial statement elements, and recording incorrect journal entries that also did not have sufficient review and approval. These deficiencies could result in a material misstatement of financial statements. Furthermore, the company's intellectual property, including licenses, was fully impaired by $2,550,000 ⁵⁸ in 2025 due to ongoing litigation involving the licensor, lack of development or commercialization activities, and significant uncertainty regarding the company's ability to utilize the licensed technology.

Management's overall tone emphasizes the company's position as a wellness consumer products company with a diverse product pipeline and a methodical approach to product development, focusing on established mechanisms of action, clinical efficacy, patent protection, and commercial stability. Despite reporting a net loss of $6,278,191 ⁵⁹ for the year ended December 31, 2025, and having an accumulated deficit of approximately $7,140,982 ⁶⁰, management believes that existing cash resources of $2,189,232 ⁶¹ are sufficient to fund operations for at least the next twelve months. Key strategic priorities include the relaunch of Photocil in the United States, targeted for 2026, and the continued commercialization and refinement of marketing strategies for the Hair Enzyme Booster (JW-700) on e-commerce platforms. The company also plans to complete the reformulation of CB-101 for eczema treatment by Q4 2025/Q1 2026, with an anticipated online launch in Q2 2026. Management intends to seek acquisition opportunities in the branded consumer products space to expand its product line and market presence.